Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: The difference of soluble and endogenous secretory RAGE

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 10, 2014, Pages 2540-2546

  Moriya, Saori ^a   Yamazaki, Masako ^a   Murakami, Hirohiko ^b   Maruyama, Kenji ^a   Uchiyama, Shinichiro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Toda Chuo Health Exam Center   (Japan)

Author keywords

Calcification; Carotid atherosclerosis; Endogenous secretory receptor for advanced glycation end products; Intima media thickness; Metabolic component; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; CHOLESTEROL; ENDOGENOUS SECRETORY RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID; ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; ISOPROTEIN;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTERY CALCIFICATION; ARTICLE; BODY MASS; CAROTID ATHEROSCLEROSIS; COMMON CAROTID ARTERY; FEMALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; WAIST CIRCUMFERENCE; WHITE MATTER; AGED; BLOOD; BLOOD VESSEL CALCIFICATION; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CLASSIFICATION; METABOLIC SYNDROME X; MIDDLE AGED; PATHOLOGY; STATISTICAL MODEL;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CAROTID STENOSIS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROTEIN ISOFORMS; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84923085645     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.05.037     Document Type: Article

References (34)

1. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem pharmacol 2010; 79:1379-1386.
2. Vazzana N, Santilli F, Cuccurullo C, et al. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009; 4:389-401.
3. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267:14998-15004.
4. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membranebound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008;22:3716-3727.
5. Parkin E, Harris B. A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10. J Neurochem 2009;108:1464-1479.
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
7. Ito C. [Report of the committee on drafting guidelines for determining health-screening grades and providing future guidance. 3. Classifications of fasting blood glucose and HbA1c]. Ningen Dock 2008;22:874-877. Japanese.
8. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Circulation 2005;112:E285-E290.
9. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351-356.
10. Koyama H, Shoji T, Yokoyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:2587-2593.
11. Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005;23:1725-1729.
12. Pullerits R, Bokarewa M, Dahlberg L, et al. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005; 7:R817-R824.
13. Zhang H, Tasaka S, Shiraishi Y, et al. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med 2008;178:356-362.
14. Muhammad S, Barakat W, Stoyanov S, et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008;28:12023-12031.
15. Frommhold D, Kamphues A, Hepper I, et al. RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 2010; 116:841-849.
16. Tang SC, Wang YC, Li YI, et al. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol 2013;33: 585-594.
17. Yokota C, Minematsu K, Tomii Y, et al. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J Neurol Sci 2009;287:41-44.
18. Hudson BI, Moon YP, Kalea AZ, et al. Association of serum soluble receptor for advanced glycation endproducts with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis 2011;216:192-198.
19. Cecil DL, Terkeltaub RA. Arterial calcification is driven by RAGE in Enpp12/2 mice. J Vasc Res 2011;48:227-235.
20. Nguyen N, Naik V, Speer MY. Diabetes mellitus accelerates cartilaginous metaplasia and calcification in atherosclerotic vessels of LDLr mutant mice. Cardiovasc Pathol 2013;22:167-175.
21. Li F, Cai Z, Chen F, et al. Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products. Basic Res Cardiol 2012;107:306.
22. Ren X, Shao H, Wei Q, et al. Advanced glycation endproducts enhance calcification in vascular smooth muscle cells. J Int Med Res 2009;37:847-854.
23. Tanikawa T, Okada Y, Tanikawa R, et al. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009; 46:572-580.
24. Basta G, Corciu AI, Vianello A, et al. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis 2010;210:614-618.
25. Kim JK, Park S, Lee MJ, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012;220:208-214.
26. Lindsey JB, de Lemos JA, Cipollone F, et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes care 2009;32:1218-1220.
27. Nasrallah MM, El-Shehaby AR, Osman NA, et al. Endogenous soluble receptor of advanced glycation endproducts (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients. Int Urol Nephrol 2012;44:1193-1199.
28. Katakami N, Matsuhisa M, Kaneto H, et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 2008;5:190-197.
29. Matsui T, Yamagishi S, Ueda S, et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2007;35:482-489.
30. Fujita M, Okuda H, Tsukamoto O, et al. Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26:e138-e142.
31. Wang L, Zhang X, Liu L, et al. Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci Lett 2010;471:152-156.
32. Basta G, Castagnini M, Del Turco S, et al. High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis. Eur J Clin Invest 2009;39:1065-1072.
33. Park HJ, Baek JY, Shin WS, et al. Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction. Circ J 2011;75:1685-1690.
34. Tang SC, Wang YC, Li YI, et al. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol 2013;33:585-594.